Arrowhead Research | ARWR - Sales Revenues


Arrowhead Research reported $73.74M in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
Agios Pharmaceuticals USD 18.8M 1.17M Mar/2026
Alnylam Pharmaceuticals USD 1.17B 70M Mar/2026
Anika Therapeutics USD 30.62M 2.8M Dec/2025
Arrowhead Research USD 73.74M 190.29M Mar/2026
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Incyte USD 1.27B 240M Mar/2026
Ionis Pharmaceuticals USD 246M 43M Mar/2026
Ligand Pharmaceuticals USD 51.72M 7.94M Mar/2026
Merck USD 16.29B 110M Mar/2026
Moderna USD 389M 289M Mar/2026
Nektar Therapeutics USD 21.81M 2.32M Dec/2025
Novartis USD 13.11B 226M Mar/2026
Sarepta Therapeutics USD 730.8M 287.9M Mar/2026
TG Therapeutics USD 194.8M 2.23M Mar/2026
Ultragenyx Pharmaceutical USD 136M 71M Mar/2026
Vertex Pharmaceuticals USD 2.99B 200M Mar/2026
Xencor USD 4.51M 23.73M Mar/2026